Andrew Satlin is VP at Intra-Cellular Therapies, Inc. (ITCI). They have made 1 open-market trade across 1 company since 2020, most recently 2020-01-09.
CIK 0001722858
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITCI | 11,338 | $1.5M |
Shares reported on the most recent Form 4, priced at the 2020-01-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITCI | SELL | 2020-01-09 | 2020-01-10 | $26.16 | $605K | -4.4% | -17.9% | -36.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.